Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 9/20 | 0.83 |
| ▸ | SSTR2 | P30874 | 14/20 | 0.80 |
| ▸ | SSTR5 | P35346 | 10/20 | 0.80 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1651014 | 1.00 | SSTR4 (0.83) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL29414558 | 1.00 | SSTR4 (0.83) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL5069978 | 0.99 | SSTR4 (0.82) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL29449384 | 0.99 | SSTR4 (0.82) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL29408685 | 0.97 | SSTR4 (0.79) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL29360979 | 0.95 | SSTR4 (0.78) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL29653935 | 0.95 | SSTR2 (0.79) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL23482744 | 0.91 | SSTR2 (0.88) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL23901126 | 0.91 | SSTR2 (0.88) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL24064978 | 0.91 | SSTR2 (0.83) | SSTR4SSTR2SSTR5SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| EP-4611839-A1 | WOUND CLEANSING JET | Aurena Laboratories Holding AB (SE) | 2025-09-10 | — | — | EP | claimed |
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | claimed |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2025-08-14 | — | — | US | claimed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | claimed |
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | claimed |
| WO-2025068850-A1 | METHOD OF TREATING CANCER | NOVARTIS AG (CH) | 2025-04-03 | — | — | WO | claimed |
| WO-2006051531-A2 | RADIOIMAGING | SPECTRUM DYNAMICS LLC (US) | 2006-05-18 | — | — | WO | claimed |
| EP-1622602-A2 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | THE GENERAL HOSPITAL CORPORATION (US) | 2006-02-08 | — | — | EP | claimed |
| US-20040253177-A1 | Fatty acid derivatives; tissue-targeted therapy; tomography; cardiovascular disorders; liver disorders; kits | GENERAL HOSPITAL CORPORATION, THE | 2004-12-16 | — | — | US | claimed |
| WO-2004093650-A2 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | THE GENERAL HOSPITAL CORPORATION (US) | 2004-11-04 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0961591-A4 | METHOD TO ENHANCE TISSUE ACCUMULATION OF RADIOLABELED COMPOUNDS | UNIV LOUISIANA STATE (US) | 2002-07-31 | — | — | EP | claimed |
| US-6180082-B1 | ADMINISTRATION OF A RADIOISOTOPIC COMPOUND BY INFUSION OVER A PERIOD OF TIME GREATER THAN TWO HOURS, PREFERABLY GREATER THAN TWELVE HOURS, GREATLY INCREASES THE MAXIMUM RADIOACTIVITY THAT ACCUMULATES IN THE TARGET CELL | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2001-01-30 | — | — | US | claimed |
| CN-1250361-A | Method to enhance tissue accumulation of radiolabeled compounds | UNIV LOUISIANA STATE (US) | 2000-04-12 | — | — | CN | claimed |
| EP-0961591-A1 | METHOD TO ENHANCE TISSUE ACCUMULATION OF RADIOLABELED COMPOUNDS | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1999026551-A1 | METHOD TO ENHANCE TISSUE ACCUMULATION OF RADIOLABELED COMPOUNDS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 1999-06-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | KRAS, NRAS, TP53 | SSTR4 4625/4885SSTR2 4568/4885SSTR5 4362/4885 |
| US-12533321-B2 | Polypeptide formulations for oral delivery | PTMS, IAPP, IGF1R | SSTR4 65/4885SSTR2 327/4885SSTR5 85/4885 |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SLC7A1, KARS1, LNPEP | SSTR4 1559/4885SSTR2 2684/4885SSTR5 1381/4885 |
| US-20040253177-A1 | Fatty acid derivatives; tissue-targeted therapy; tomography; cardiovascular disorders; liver disorders; kits | FABP1, FABP3, FFAR2 | SSTR4 198/4885SSTR2 278/4885SSTR5 242/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | SSTR4 30/4885SSTR2 75/4885SSTR5 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.